Victoria Richon is a scientifically trained executive with leadership experience in biotechnology companies, global pharmaceutical companies and academia. Before joining Entact, Dr. Richon was the President and CEO of Ribon Therapeutics, a clinical stage biotechnology company focused on the discovery and development of first-in-class cancer and inflammatory disease medicines. Previously, she was the Vice President and Global Head of Oncology Research and Translational Medicine at Sanofi where she was responsible for the oncology drug discovery and translational medicine portfolio. Prior to Sanofi, Dr. Richon was Vice President of Biological Sciences at Epizyme, Inc., a biotechnology company pioneering the discovery and development of novel therapeutics focused on epigenetics, including Tazverik, the first EZH2 inhibitor approved by the FDA for the treatment of advanced epithelioid sarcoma and follicular lymphoma. Earlier in her career, she was Founder and Executive Director of Aton Pharmaceuticals which was acquired by Merck & Co. Aton was formed to develop HDAC inhibitors, including Zolinza, the first HDAC inhibitor approved by the FDA. Dr. Richon is a member of the Board of Directors of HotSpot Therapeutics, Inc.

Dr. Richon is the author of over 100 papers and carried out postdoctoral studies at Memorial Sloan-Kettering Cancer Center. She received her PhD in Biochemistry at the University of Nebraska Medical Center and a BA in Chemistry at the University of Vermont.